Title:
ボツリヌス毒素医薬組成物
Document Type and Number:
Japanese Patent JP5080902
Kind Code:
B2
Abstract:
A neurotoxin containing pharmaceutical composition, comprising a polysaccharide, an amino acid and/or recombinantly made albumin as substitutes for natural albumin, is new. Independent claims are also included for the following: (1) pharmaceutical composition comprising a neurotoxin, and a polysaccharide which stabilizes the neurotoxin; (2) pharmaceutical composition comprising a botulinum toxin, and a hydroxyethyl starch (3) pharmaceutical composition comprising a botulinum toxin, a polysaccharide, and an amino acid or polyamino acid (4) pharmaceutical composition comprising a botulinum toxin, and a recombinantly made albumin; (5) pharmaceutical composition comprising a botulinum toxin, and an amino acid; (6) pharmaceutical composition suitable for injection into humans, comprising a botulinum toxin, and a polysaccharide which comprises linked glucopyranose units, each of which has a plurality of hydroxyl groups, an average of 6-9 of the hydroxyl groups present on each 10 of the glucopyranoses present in the polysaccharide are substituted, through an ether linkage, with a compound of formula (CH 2) nOH (7) stable, high potency, non-pyrogenic, vacuum-dried botulinum toxin type A pharmaceutical composition, comprising a botulinum toxin type A complex, a polysaccharide, and an amino acid or polyamino acid, the formulation is albumin-free, has a 1 year shelf life at -5 [deg]C, with 90 % potency immediately after reconstitution with saline or water and 80 % potency 72 hours after reconstitution and storage at 2 [deg]C; and (8) device for injecting a pharmaceutical composition, comprising a dual chamber prefilled syringe, one chamber of which contains a botulinum toxin and the other of which contains a diluent or buffer. n : 1-4. ACTIVITY : Antispasmodic; neuroprotective. No biological data is given. MECHANISM OF ACTION : None given.
Inventors:
Terence Jay Hunt
Application Number:
JP2007211802A
Publication Date:
November 21, 2012
Filing Date:
August 15, 2007
Export Citation:
Assignee:
ALLERGAN,INCORPORATED
International Classes:
A61K38/00; C12N9/96; A61K9/08; A61K9/14; A61K9/19; A61K35/74; A61K38/16; A61K38/46; A61K38/48; A61K39/08; A61K45/00; A61K47/18; A61K47/36; A61K47/42; A61M5/19; A61M5/24; A61M5/28; A61P21/00; A61P21/02; A61P25/00; A61P27/02; C07K14/195; C12P21/02
Domestic Patent References:
| JP59196821A | ||||
| JP60258125A | ||||
| JP11500404A | ||||
| JP5005065A | ||||
| JP1216936A | ||||
| JP11507072A |
Foreign References:
| WO1996011699A1 |
Other References:
日本医薬品添加剤協会編,「ヒドロキシプロピルスターチ」,医薬品添加物事典,1994年 1月14日,p. 105-106
Goodnough MC, et al.,Stabilization of botulinum toxin type A during lyophilization,Applied and Environmental Microbiology,1992年10月,Vol. 58, No. 10,p. 3426-3428
Goodnough MC, et al.,Stabilization of botulinum toxin type A during lyophilization,Applied and Environmental Microbiology,1992年10月,Vol. 58, No. 10,p. 3426-3428
Attorney, Agent or Firm:
Mitsuo Tanaka
Takuji Yamada
Kyousei Tamura
Yasuo Shibata
Nagatoshi Shinagawa
Takuji Yamada
Kyousei Tamura
Yasuo Shibata
Nagatoshi Shinagawa